Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) ? agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Abstract: Provided is a method developed for producing a thread bundle with high efficiency in terms of spun thread collection and without causing mechanical damage to a foothold silk thread spun by a bagworm onto a base material. After a bagworm is placed along with a solvent-soluble base material and allowed to spin the foothold silk thread onto the surface of the base material, the base material is dissolved with a solvent to separate the foothold silk thread therefrom.

Abstract: A technique is provided for improving the stability of a halogenated isoquinoline derivative with respect to light in an aqueous composition. A pharmaceutical preparation obtained by storing an aqueous composition comprising a compound represented by Formula (1): wherein X represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, in a package that blocks a ray with a wavelength of 300 to 335 nm.

Abstract: Provided is a novel preventing and/or treating agent useful for prevention and/or treatment of carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect. The present invention relates to a medicament for preventing and/or treating carnitine deficiency, or a disease for which supplementation of carnitine may have a therapeutic effect, the medicament comprising a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate thereof.

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(-)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

Abstract: The present invention addresses the problem of providing a pharmaceutical composition/drug combination which makes it possible to prevent and/or treat dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) ? agonist and an ATP citrate lyase (ACL) inhibitor for preventing and/or treating dyslipidemia such as hypercholesterolemia and hypertriglyceridemia, or cardiovascular diseases such as arteriosclerosis and cardiovascular events.

Abstract: An ophthalmic photographing apparatus enables easy detection of a pupil diameter. The ophthalmic photographing apparatus is provided with an anterior ocular segment illumination unit for illuminating an anterior ocular segment of a subject eye with invisible light, an imaging element that is sensitive to at least invisible light and captures an image of the subject eye, and a processing unit for processing the image captured by the imaging element. When an image of an index projected onto the anterior ocular segment satisfies a predetermined condition, the processing unit starts detection of a pupil diameter of the subject eye by using the image on the imaging element formed by invisible light reflected from the anterior ocular segment.

Abstract: A non-cellular dental tissue regeneration promoting kit is provided that makes effective dental tissue regeneration possible without transplantation of autologous or allogeneic stem cells or components derived from stem cells. The kit comprises: a pretreatment agent comprising a serine protease; and a non-cellular root canal filling material, the non-cellular root canal filling material comprising: a regeneration promoting compound including at least one of a CCR3 antagonist, a CCL11 neutralizing antibody, and an ALK5 inhibitor; and an extracellular matrix. The kit is preferably used for middle-aged or elderly individuals.

Abstract: The present invention provides a novel copolymer available for a drug delivery technique. More particularly, a novel copolymer for a drug delivery carrier targeting a tumor is provided. The present invention relates to a copolymer comprising structural units represented by the following formulas (A), (B), and (C): wherein R1, R2, and R3 are the same or different and represent a hydrogen atom or a C1-3 alkyl group, R4 represents a C1-3 alkyl group, R5 represents a hydrogen atom, a C1-18 alkyl group, a 3- to 8-membered cycloalkyl group optionally having a substituent, an adamantyl group, a C6-18 aryl group optionally having a substituent, or a 5- to 10-membered heteroaryl group optionally having a substituent, X1, X2, and X3 are the same or different and represent an oxygen atom, a sulfur atom, or N—R7, R6 represents a hydrogen atom, a leaving group, or a linker, R7 represents a hydrogen atom or a C1-3 alkyl group, m represents an integer of 1 to 100, and n represents an integer of 0 to 3.

Abstract: According to one or more embodiments of the disclosure, a lens barrel includes an operation member and a knob. The operation member is disposed to be rotatable in a circumferential direction with respect to a lens barrel body. The knob is restricting and fixing rotation of the operation member in the circumferential direction. The lens barrel further includes a knob falling-off prevention member capable of switching between a first state of making the knob detachable from the lens barrel body and a second state of making the knob non-detachable from the lens barrel body.

Abstract: Developed and provided is a method of collecting a large amount of high-quality bagworm silk threads having no contaminant from bagworm nests in a convenient manner and at low cost. The habit of bagworms is utilized to allow a bagworm to build a nest using solvent-soluble substances or thermally meltable substances as nest materials, followed by dissolving or melting the nest materials to separate the nest material from the bagworm silk threads, whereby only pure bagworm silk threads constituting the bagworm nest can be obtained.

Abstract: An object of the present invention is to develop: a method of efficiently producing a long bagworm silk thread containing no contaminant while preventing a change in the spinning direction and the runaway of the bagworm from a rail, and alleviating a burden on the bagworm; and an apparatus for implementing the thread-producing method. Provided is an apparatus for producing a bagworm silk thread, having a movable rail having a width smaller than the maximum width between the right and left legs of a bagworm and configured to move in the longitudinal direction and to be able to hold with the legs of the bagworm; and a fixator configured to fix a bagworm, wherein the fixator is placed at a position such that the fixed bagworm can hold the movable rail.

Abstract: A simple and efficient breeding method for the bagworm moth is provided, as well as a device for performing the method. Also developed and provided is a method of easily collecting eggs from a bagworm moth, an egg collection device for bagworm moths composed of a tubular container. A bagworm moth breeding method and egg collection method performed using the device are also described.

Abstract: To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Abstract: Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and one or more selected from the group consisting of a metal oxide, a dihydric alcohol, an ester species and a silicic acid compound and which has excellent storage stability. The pharmaceutical composition includes the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-4): (B-1) a metal oxide; (B-2) a dihydric alcohol; (B-3) an ester species; and (B-4) a silicic acid compound, with component (A) and component (B) being substantially in non-contact with each other.

Abstract: In order to obtain an inspection image without blown-out highlights generated due to specular reflection or the like or blocked-up shadows generated at a position to which light hardly reaches, an image processing device includes a plurality of light sources that irradiates an object with light and a control circuit that controls light emission of the plurality of light sources, a camera that photographs the object, and a processor that controls switching of a light emission pattern of the plurality of light sources and controls photographing execution timing of the camera, controls the plurality of light sources to emit light with a plurality of light emission patterns, performs photographing at timings during at least two or more patterns among the plurality of light emission patterns to obtain a plurality of intermediate images, and generates one final image based on the plurality of obtained intermediate images.

Abstract: An imaging device according to the present invention includes an illumination unit 20 containing a light source 21 for emitting illumination light 2, and a lens group 22 for irradiating an imaging object 1 with the illumination light 2 emitted from the light source 21, and an imaging unit 10 for imaging the imaging object 1. A part of the illumination light 2 is shielded by a light shielding component 40.

Abstract: Provided is a novel inhalant as a therapeutic agent for COVID-19. The present invention relates to an inhalant containing cepharanthine.